Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | CAR T-cell therapy and BiTEs for myeloma

Philippe Moreau • 16 Jun 2020
EHA 2020
Multiple Myeloma Antibodies CAR-T Idecabtagene vicleucel Teclistamab
CARTITUDE-1 KarMMa

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, outlines results of the use of teclistamab, a BCMA x CD3 bispecific antibody in relapsed/refractory multiple myeloma (MM) patients, in addition to updates from KarMMa and CARTITUDE-1, evaluating the efficacy and safety of CAR T-cell therapies in MM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Philippe Moreau

Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma 1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy 4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
Optimal treatment strategies for multiple myeloma 3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
Optimal treatment sequencing for relapsed/refractory myeloma 1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals